Table 4. Antitumor efficacy parameters.
| Parameters | EP | TPT | Total (N=29) | |||
|---|---|---|---|---|---|---|
| 1 line (n=24) | ≥2 lines (n=2) | Total (N=26) | ≥2 lines (n=3) | |||
| ORR, n (%; 95% CI) | 20 (83.3; 62.6–95.3) | 1 (50.0; 1.3–98.7) | 21 (80.8; 60.6–93.4) | 0 (0; 0–70.8) | 21 (72.4; 52.8–87.3) | |
| DCR, n (%; 95% CI) | 24 (100.0; 85.8–100.0) | 1 (50.0; 1.3–98.7) | 25 (96.2; 80.4–99.9) | 3 (100.0; 29.2–100.0%) | 28 (96.6; 82.2–99.9) | |
| mDOR (95% CI) | 6.9 (5.1–9.2) | 4.4 (–) | 6.8 (5.1–9.2) | – | 6.8 (5.1–9.2) | |
CI, confidence interval; DCR, disease control rate; EP, platinum/etoposide; mDOR, median duration of response; N, total number of patients; n, number of patients in a respective category; ORR, objective response rate; TPT, topotecan.